The COIN trial was a randomized trial that examined the effects of adding cetuximab, an anti-EGFR monoclonal antibody, to the standard oxaliplatin-based chemotherapy regimens as a first-line treatment for patients with advanced CRC; the results revealed that the addition of cetuximab did not affect OS or PFS but increased tumor response rates in patients with the wild-type KRAS genotype [20]. Here, KRAS is linked to neoplasm.